GW642444M

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

Study to Assess GW642444 in Asthma Patients

CompletedNCT00381667

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2006-08-31End: 2007-01-31Updated: 2016-10-28

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

CompletedNCT00519376

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2007-08-31End: 2007-11-30Updated: 2017-03-23

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

CompletedNCT00600171

GlaxoSmithKlineAsthma

Start: 2007-12-31End: 2008-09-30Updated: 2016-12-16

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

CompletedNCT01128595

GlaxoSmithKlineAsthma

Start: 2010-05-31End: 2011-05-31Updated: 2017-01-18

Related Papers

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial.

2012-06-2712 citations